Peptide Vaccine Candidates for Prostate Cancer Target PSMA and STEAP1 with T Cell Activation | Research

The takeaway

HLA-A*02:01-restricted peptide epitopes from PSMA and STEAP1 induced antigen-specific T cell responses in preclinical assessment, supporting peptide-based immunotherapy development for prostate cancer.

Immune T cells activated
Peptide fragments from prostate cancer proteins successfully trained immune cells to recognize and attack cancer cells in preclinical testing

What the researchers found

HLA-A*02:01-restricted PSMA and STEAP1 epitopes induced antigen-specific T cell responses in preclinical assessment, demonstrating immunogenicity for prostate cancer peptide vaccine development.

Why it matters

Prostate cancer is the most common male cancer. Peptide vaccines could provide targeted immunotherapy with minimal side effects.

How the study worked

Preclinical evaluation of HLA-A*02:01-restricted peptide epitopes from PSMA and STEAP1, including immunogenicity testing and T cell response characterization.

What this study cannot tell us

Preclinical only. HLA-A*02:01 covers ~50% of population. Clinical immunogenicity and anti-tumor efficacy not established.

How to read the evidence

Preclinical immunogenicity assessment. Standard for early-stage peptide vaccine development.

When this study was published

Published in 2025.

The bigger picture

Peptide-based prostate cancer vaccines could complement existing treatments (surgery, radiation, hormonal) with targeted immune responses.

Questions still open

Would these peptides produce clinical anti-tumor responses in prostate cancer patients?
Can the approach be expanded to other HLA types?
Should peptide vaccines be combined with checkpoint inhibitors for prostate cancer?

Common questions

Could a vaccine treat prostate cancer?

Therapeutic peptide vaccines teach the immune system to recognize and attack prostate cancer cells. These PSMA and STEAP1 peptides successfully activated cancer-killing immune cells in lab testing.

Is this available?

Not yet. Preclinical testing proved the peptides activate the right immune cells. Clinical trials in prostate cancer patients are the next step.

Read the original research

Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.

Drug design, development and therapy, 20, 576346

View on PubMed ↗Publisher’s paper ↗

Citation

Huang, Yueting; Yang, Yang; Xie, Yanni; Shu, Yue; Yang, Siqi; Long, Xuezhi; Wen, Zhipeng; Duan, Xiaolu; Fu, Li; Gu, Di; Huang, Tuxiong. (2026). Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.. Drug design, development and therapy, 20, 576346. https://doi.org/10.2147/DDDT.S576346